ROCK1 Inhibitors
1 drugsAbout ROCK1
ROCK1 is a serine/threonine kinase involved in cell motility, adhesion, and contraction by regulating the actin cytoskeleton. It influences various biological functions, making it a potential target for drug development.
Currently, there is no genetic evidence directly linking ROCK1 to specific diseases. However, its involvement in fundamental cellular mechanisms suggests potential therapeutic applications across various disease areas.
ROCK1 is targeted by one FDA-approved small molecule drug, REZUROCK, approved in 2021. REZUROCK's therapeutic area is categorized as 'Other', highlighting potential for ROCK1 inhibition to address unmet needs.
Top ROCK1 Drugs
KADMON PHARMS LLC is the only company with an approved drug targeting ROCK1.
The single-player competitive landscape suggests high barriers to entry or limited commercial attractiveness.
ROCK1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ROCK1, using small molecule modality.
The lack of modality diversity suggests an opportunity to explore alternative approaches like antibodies or PROTACs.
ROCK1 Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ROCK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 7 | 0 | 5 | 100% |
| Phase 2 | 17 | 5 | 4 | 7 | 56% |
| Phase 3 | 3 | 0 | 0 | 3 | - |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ROCK1 Drug Approval Timeline (2021 - 2021)
REZUROCK was the first and most recent drug approved for ROCK1 in 2021.
The recent approval suggests renewed interest in ROCK1, but further approvals are needed to confirm sustained viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ROCK1. A trial counts if an approved drug acting on ROCK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.